Srinivas Akkaraju - 16 Sep 2022 Form 4/A - Amendment Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
20 Apr 2023, 16:39:37 UTC
Date Of Original Report
19 Sep 2022
Previous filing
28 Jul 2022
Next filing
23 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Award +691,489 +364% 881,450 16 Sep 2022 See footnote F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +12,000 $0.000000 12,000 16 Sep 2022 Common Stock 12,000 $7.35 Direct F4
transaction SYRS Restricted Stock Units Award $0 +8,000 $0.000000 8,000 16 Sep 2022 Common Stock 8,000 Direct F5, F6
transaction SYRS Warrants (right to buy) Award +691,489 691,489 16 Sep 2022 Common Stock 691,489 $10.34 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The purchase price for the reported securities was $9.40 per share of Common Stock and accompanying warrant to purchase one share of Common Stock.
F2 Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
F3 Securities held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein.
F4 The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
F5 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F6 These RSUs will vest in three equal annual installments commencing on September 16, 2023.

Remarks:

This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct the inadvertent omission of the Reporting Person's indirect beneficial ownership of certain securities held by Samsara Biocapital.